Discover and read the best of Twitter Threads about #DrLindaLiau
Most recents (6)
$NWBO #DCVaxL
The #PolyICLC adjuvant has already been approved for adjuvant use in other cancers. Under new FDA rules, real world data and validation of the results already seen may make it very easy not only to expand the label and access to #Hiltonol, but also ease insurance / Medicare if
If #DCVaxL is approved. It should be straightforward to add #PolyICLC $NWBO.
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
See, “Poly ICLC (Hiltonol®): an immune adjuvant targeting the Toll-like receptor 3 (TLR3) pathway; approved for subsets of patients with squamous cell carcinoma”
cancerresearch.org/treatment-type…
A lot of people are starting to notice IMHO. $NWBO #DCVaxL
Phase 3 results: $NWBO #DCvaxL
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination w/Extension of Survival Among Patients w/[BOTH] #NewlyDiagnosed & #Recurrent #Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial #CancerVaccine
jamanetwork.com/journals/jamao…
Mind blowing interim, unpublished data #DCVaxL data from UCLA #DrLindaLiau presentation for use with adjuvant #PolyICLC #TLR3Agonist #Hiltonol #glioblastoma #cancervaccine
Exploring Adjuvants with #DCVaxL: POLY ICLC TLR 3 Agonist adjuvant discussion, #DrLindaLiau, early trial P 1. Using adjuvants w/ #DCVaxL $NWBO #Murcidencel #DCVax
Survival Data w/Adjuvants, small early trial:
Survival Data w/Adjuvants, small early trial:
Fuller Discussion re early trial with #DCVaxL + adjuvants, including Poly ICLC:
Re single agent checkpoint inhibitors, without DCVaxL, in Glioblastoma:
$NWBO #DCVaxL New name #murcidencel
SNO Abstract, just released, for presentation by #DrLindaLiau on November 20th:
Background: Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years.
SNO Abstract, just released, for presentation by #DrLindaLiau on November 20th:
Background: Standard of care (SOC) and patient survival in glioblastoma have changed little in the past 17 years.
We evaluated in a phase 3 trial whether adding an autologous tumor lysate-loaded dendritic cell vaccine (murcidencel) to SOC extends survival. Patients and
Methods: Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo.
Methods: Newly diagnosed glioblastoma patients were randomized 2:1 to either murcidencel or placebo.
Under a crossover design, all patients could receive murcidencel following tumor recurrence. All parties remained blinded regarding treatments before recurrence. Patients thus received murcidencel at new diagnosis (nGBM) or at recurrence (rGBM) following crossover from placebo.
Dr. Keyoumars Ashkan #DrKeyoumarsAshkan Surgeon & professor, and he also ran the European trials for #DCVaxL from $NWBO
Professor Ashkan performs life-saving awake brain tumour surgery while patient plays violin! via @YouTube
1/ Re $NWBO and #DCVaxL aka "ATL-DC" in brief:
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
#DrLindaLiau, principal investigator for a Phase 3 #DCVaxL trial recently gave a lecture covering the #DCVaxLComboTrial with #Keytruda.
2/ $NWBO and UCLA have a patent application pending approval for immunotherapy combinations with #DCVaxL.
3/ The #DCVaxLComboTrial appears to be intended to further the patent process and also to likely advance new commercial opportunities, including potential partnerships, for $NWBO. Many commentators have suggested some obvious potential partners.
